$FDMT

4D Molecular Therapeutics, Inc. presented at the Barclays 28th Annual Global Healthcare Conference, highlighting advancements in their gene therapy platforms. The presentation emphasized the company's innovative approaches that could position it favorably in the competitive biotech sector. Investors are particularly focused on upcoming data releases that may validate the company's technology and lead to potential partnerships or investments. The market is reacting positively to their commitment to advancing scientific research and development. Overall, the event has sparked renewed interest in FDMT's growth potential amidst an evolving healthcare landscape.